The 2023 British Thoracic Society Guideline for Pleural Disease Update on Malignant Pleural Effusion
Journal of Respiration · 26.11.2024 · 4 (4) · 210-222
DOI: 10.3390/jor4040019 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Respiration, online erschienen am 26.11.2024. Verfasst von Kavita Sivabalah und 6 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The management of malignant pleural effusions (MPEs) has developed hugely since the publication of the management of an MPE: British Thoracic Society (BTS) Pleural Disease Guideline 2010. The presence of an MPE reflects advanced or metastatic disease (excluding malignant pleural mesothelioma) and thus the management of MPE often focuses on symptomatic relief of symptoms and improving quality of life. We provide a review of the 2023 BTS guidance in relation to malignant pleural effusions and specific points on imaging and systemic anti-cancer treatment by concentrating on a hypothetical patient vignette.
Zitieren
APA
Sivabalah, K., Balata, H., Craig, C., Alsaaty, A., Conroy, K., Ong, W. H., & Aujayeb, A. (2024). The 2023 British Thoracic Society Guideline for Pleural Disease Update on Malignant Pleural Effusion. Journal of Respiration, 4(4), 210-222. https://doi.org/10.3390/jor4040019
Vancouver
Sivabalah K, Balata H, Craig C, Alsaaty A, Conroy K, Ong WH, et al. The 2023 British Thoracic Society Guideline for Pleural Disease Update on Malignant Pleural Effusion. Journal of Respiration. 2024;4(4):210-222. doi:10.3390/jor4040019
BibTeX
@article{Sivabalah2024,
author = {Sivabalah, Kavita and Balata, Haval and Craig, Chris and Alsaaty, Alaa and Conroy, Kevin and Ong, Wei Hann and Aujayeb, Avinash},
title = {The 2023 British Thoracic Society Guideline for Pleural Disease Update on Malignant Pleural Effusion},
journal = {Journal of Respiration},
year = {2024},
volume = {4},
number = {4},
pages = {210--222},
doi = {10.3390/jor4040019}
}
EUVIMED